Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical Center, New York, New York.
Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12.
The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers. SIGNIFICANCE: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes..
新型冠状病毒病 2019（COVID-19）大流行导致肿瘤学实践发生了巨大变化。目前尚不清楚程序性死亡 1（PD-1）阻断疗法是否会影响癌症患者 COVID-19 的疾病严重程度。为了解决这一不确定性，我们检查了连续诊断出患有 COVID-19 的肺癌患者，并根据是否接受过 PD-1 阻断治疗来检查严重程度。总体而言，肺癌患者 COVID-19 的严重程度很高，包括超过一半的患者需要住院治疗，近四分之一的患者死亡。如预期的那样，先前的 PD-1 阻断与吸烟状况有关。在调整了吸烟状况后，PD-1 阻断暴露与 COVID-19 严重程度增加无关。PD-1 阻断似乎不会影响肺癌患者 COVID-19 的严重程度。意义：COVID-19 大流行期间肿瘤学实践中的一个关键问题是 PD-1 阻断疗法是否会影响 COVID-19 的严重程度。我们对肺癌患者的分析支持 PD-1 阻断治疗以实现最佳癌症结果的安全性。
